SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
1.225
-0.225 (-15.52%)
At close: Jan 13, 2026, 4:00 PM EST
1.200
-0.025 (-2.04%)
After-hours: Jan 13, 2026, 7:59 PM EST
SciSparc Revenue
SciSparc had revenue of $1.31M in the twelve months ending September 30, 2025, up 187.98% year-over-year. In the year 2024, SciSparc had annual revenue of $1.31M, down -54.64%.
Revenue (ttm)
$1.31M
Revenue Growth
+187.98%
P/S Ratio
3.07
Revenue / Employee
$653,000
Employees
2
Market Cap
4.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.31M | -1.57M | -54.64% |
| Dec 31, 2023 | 2.88M | 1.53M | 113.73% |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SPRC News
- 19 hours ago - SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity - GlobeNewsWire
- 1 day ago - SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance - GlobeNewsWire
- 5 days ago - Neurothera Labs Announces Results of AGM - TheNewswire
- 14 days ago - SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects - GlobeNewsWire
- 14 days ago - Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects - TheNewswire
- 6 weeks ago - SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - GlobeNewsWire
- 6 weeks ago - Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - TheNewswire
- 6 weeks ago - SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio - GlobeNewsWire